Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 4/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.51 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.51 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.51 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.51 |
| ▸ | MAPK6 | Q16659 | 1/20 | 0.51 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 4/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL509384 | 0.90 | ADORA1 (0.51) | ADORA1ADORA3ADORA2AMAPK1MAP2K4 | |
| SCHEMBL509599 | 0.82 | ADORA1 (0.62) | ADORA1ADORA3ADORA2AMAPK1KDM4E | |
| SCHEMBL11379233 | 0.79 | ADORA1 (0.51) | ADORA1ADORA3ADORA2AKDM4EALDH1A1 | |
| SCHEMBL11371595 | 0.76 | ADORA1 (0.51) | ADORA1ADORA3ADORA2AKDM4EALDH1A1 | |
| SCHEMBL509097 | 0.76 | XDH (0.50) | ADORA1ADORA2AALDH1A1SMN1; SMN2IDO1 | |
| SCHEMBL510204 | 0.73 | RAD52 (0.49) | ADORA1ADORA2AMAPK1KDM4EALDH1A1 | |
| SCHEMBL11374803 | 0.73 | ADORA1 (0.56) | ADORA1ADORA3ADORA2AMAPK1KDM4E | |
| SCHEMBL509858 | 0.72 | SYK (0.56) | KDM4EALDH1A1SMN1; SMN2POLBIDO1 | |
| SCHEMBL25375241 | 0.70 | RAB9A (0.48) | ADORA1ADORA3ADORA2AKDM4EALDH1A1 | |
| SCHEMBL30030511 | 0.70 | KDM4E (0.66) | MAPK1MAP2K4MAPKAPK2MAPKAPK3MAPK6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314123-B2 | 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| CN-102532020-A | 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS INC | 2012-07-04 | — | — | CN | disclosed |
| EP-2423196-A1 | 5, 6 or 7-substituted-3-phenylisoquinolinamine derivatives and therapeutic use thereof | Rexahn Pharmaceuticals, Inc. (US) | 2012-02-29 | — | — | EP | disclosed |
| CN-101573337-B | 5, 6 or 7-substituted-3- (hetero) aryl-isoquinolinamine derivatives as antitumor agents | REXAHN PHARMACEUTICALS, INC. (US) | 2012-02-08 | — | — | CN | disclosed |
| US-20120029012-A1 | 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF | REXAHN PHARMACEUTICALS, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| US-8034829-B2 | e.g. 3-(3-methoxyphenyl)isoquinolin-1-amine; antiproliferative and antigrowth agent; breast tumors, prostate tumors, colon tumors, ovary tumors, kidney tumors, pancreas tumors, glioblastoma and melanoma. | REXAHN PHARMACEUTICALS, INC. (US) | 2011-10-11 | — | — | US | disclosed |
| CN-101573337-A | 5, 6 or 7-substituted-3- (hetero) aryl-isoquinolinamine derivatives as antitumor agents | REXAHN PHARMACEUTICALS INC (US) | 2009-11-04 | — | — | CN | disclosed |
| US-20080182871-A1 | 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | REXAHN PHARMACEUTICALS, INC. (US) | 2008-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080182871-A1 | 5, 6, or 7-Substituted - 3-(hetero) arylisoquinolinamine derivatives and therapeutic use thereof | FANCD2, NRAS, CCND2 | ADORA1 2974/4885ADORA3 1788/4885ADORA2A 1444/4885 |
| US-20120029012-A1 | 5, 6, or 7-SUBSTITUTED -3-(HETERO) ARYLISOQUINOLINAMINE DERIVATIVES AND THERAPEUTIC USE THEREOF | FANCD2, NRAS, CCND2 | ADORA1 2974/4885ADORA3 1788/4885ADORA2A 1444/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.